Trial Profile

A Single-Arm, Registration-Enabling Study to Evaluate Flotetuzumab in Patients with Refractory Acute Myeloid Leukaemia (AML)

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 04 Mar 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Flotetuzumab (Primary)
Indications Acute myeloid leukaemia
Focus Registrational; Therapeutic Use
Sponsors MacroGenics

Most Recent Events

25 Feb 2021 According to a MacroGenics media release, the company expects to completing full enrollment of this study in 2022.
06 Dec 2020 According to a MacroGenics media release, study is currently ongoing, with a total of up to 200 patients planned for enrollment for registrational purposes.
06 Dec 2020 According to a MacroGenics media release, data (cut-off date of November 10, 2020) were presented at the 62nd Annual Meeting of the American Society of Hematology (ASH) 2020.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com